European Medicines Agency

Doc. Ref. EMEA/626714/2008
P/123/2008

EUROPEAN MEDICINES AGENCY DECISION

of 5 December 2008

on the application for modification of an agreed Paediatric Investigation Plan for clopidogrel (Iscover) EMEA-000050-PIP01-07-M01 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 5 December 2008

on the application for modification of an agreed Paediatric Investigation Plan for clopidogrel (Iscover) EMEA-000050-PIP01-07-M01 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the decision P/26/2008 of the European Medicines Agency on 23 May 2008,

Having regard to the application submitted by Bristol Myers Squibb Pharma EEIG on 5 September 2008 under Article 22 of Regulation (EC) No 1901/2006 as amended for changes to an agreed Paediatric Investigation Plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 October 2008, in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given, a positive opinion,

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the modification of on agreed Paediatric Investigation Plan.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A modification of an agreed Paediatric Investigation Plan concerning changes for clopidogrel (Iscover), oral formulation and film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision, that supersedes previous decision of the European Medicines Agency P/26/2008 on identical matter, is addressed to Brystol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH.

Done at London, 5 December 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

EMEA/626714/2008
EMEA-000050-PIP01-07-M01

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON MODIFICATION OF THE PAEDIATRIC INVESTIGATION PLAN FOR

Scope of the application

Active substance: Clopidogrel

Invented name: Iscover

Condition(s): Thromboembolic events

Pharmaceutical form(s): Oral formulation, film-coated tablet

Route(s) of administration: Oral use

Name/corporate name of the PIP applicant: Bristol Myers Squibb Pharma EEIG

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bristol Myers Squibb Pharma EEIG submitted to the EMEA on 5 September 2008 an application for modification of the agreed paediatric investigation plan as set out in the EMEA decision P/26/2008 of 23 May 2008.

The procedure started on 25 September 2008.

Scope of the modification

The modification concerned the type of design of one clinical study.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report to agree the modification of the paediatric investigation plan.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex and appendix(ces).

London, 17 October 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S) / DISEASE(S)

Thromboembolic events

B. WAIVER

- **Condition**

Atherothrombotic events

- **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:
Children aged 0 to less than 18 years for the film-coated tablet and the oral solution for oral use

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Thromboembolic events

- **Paediatric investigation plan indication**

Prevention of thrombosis and thromboembolic events in children at risk

- **Subset(s) covered**

Children aged 0 to less than 18 years

- **Formulation(s)**

Oral formulation, film-coated tablet

- **Studies / Measures**

#	Area	Subarea	Description
1	Clinical	Pharmaco-kinetic	Open, cross-over, randomized, mono-centre bioequivalence study of the 75 mg tablet and 75 mg oral solution of clopidogrel after single oral administration to young healthy men*
2	Clinical	Pharmaco-kinetic	Multi-centre, randomised, double-blind, placebo-controlled dose-finding study and pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in neonates and infants at risk for thrombosis
3	Clinical	Efficacy and safety	Randomised, multi-centre, double-blind, placebo-controlled efficacy and safety study of clopidogrel in neonates and infants with systemic-to-pulmonary artery shunt
4	Clinical	Safety	Double-blind extension phase of study #3 for children aged 1 year and older
5	Clinical	Pharmaco-dynamic	Open-label, non-comparative, pharmacodynamic, safety and descriptive efficacy study of clopidogrel in children at risk for thrombotic and / or thromboembolic events aged 2 to less than 18 years

***Study completed**

Need for paediatric measures in a EU-Risk Management Plan: Yes

Date of completion of the paediatric investigation plan: By June 2014

A deferral has been granted: Yes

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/98/070/001a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	28
EU/1/98/070/001b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	28
EU/1/98/070/002a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	50
EU/1/98/070/002b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	50
EU/1/98/070/003a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	84
EU/1/98/070/003b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	84
EU/1/98/070/004a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	100
EU/1/98/070/004b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	100
EU/1/98/070/005a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	30
EU/1/98/070/005b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	30
EU/1/98/070/006a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	90
EU/1/98/070/006b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	90
EU/1/98/070/007a	Iscover	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	14
EU/1/98/070/007b	Iscover	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	14
EU/1/98/070/008	Iscover	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	4 x 1
EU/1/98/070/009	Iscover	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 x 1
EU/1/98/070/010	Iscover	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	100 x 1